U.S. Midterms 2026: Election Implications for Markets, Sectors, & Policy -- Watch Webinar Replay

Solutions
- Research Type
  - ETF Data & AnalyticsThe data and analytics you need to navigate the ETF universe.
  - ETF & Mutual Fund ResearchA forward focused, holistic approach to fund insights.
  - Forensic Accounting ResearchUnderstand implications of public company financial reporting.
  - Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
  - Public Policy & Legal ResearchIdentify opportunity and risk driven by public policy and the courts.
  - Technical ResearchGiving you confidence to navigate any market cycle.
Who We Serve
- Client Type
  - Wealth ManagementFull-service Broker-Dealers, Online Broker-Dealers, Wealth Management Firms, Private Banks, RIAs
  - Institutional InvestorsHedge Funds, Asset Managers, Pension Funds, Sovereign Wealth Funds, Private Equity, Family Offices
  - Financial AdvisorsFinancial Advisors, Relationship Managers, Wealth Managers
  - Individual InvestorsSelf-directed individual investors
Blog
Insights
About
- About CFRA
  - Contact Us
  - Careers
Login

Solutions
- Research Type
  - ETF Data & AnalyticsThe data and analytics you need to navigate the ETF universe.
  - ETF & Mutual Fund ResearchA forward focused, holistic approach to fund insights.
  - Forensic Accounting ResearchUnderstand implications of public company financial reporting.
  - Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
  - Public Policy & Legal ResearchIdentify opportunity and risk driven by public policy and the courts.
  - Technical ResearchGiving you confidence to navigate any market cycle.
Who We Serve
- Client Type
  - Wealth ManagementFull-service Broker-Dealers, Online Broker-Dealers, Wealth Management Firms, Private Banks, RIAs
  - Institutional InvestorsHedge Funds, Asset Managers, Pension Funds, Sovereign Wealth Funds, Private Equity, Family Offices
  - Financial AdvisorsFinancial Advisors, Relationship Managers, Wealth Managers
  - Individual InvestorsSelf-directed individual investors
Blog
Insights
About
- About CFRA
  - Contact Us
  - Careers
Login

Fundamental, Research

Life Sciences Tools & Services: Upgrading Our Outlook to Positive from Neutral

Daniel Rich, CFA, Senior Equity Analyst

Summary

Is the Life Sciences Tools & Services industry approaching a turning point?

After a period of weaker biotech funding, inventory destocking, and valuation pressure, the outlook is beginning to improve. CFRA Research has upgraded its 12-month outlook on the S&P Composite 1500 Life Sciences Tools & Services sub-industry to Positive from Neutral, as stronger biopharma funding and improving company results point to a more favorable environment.

But how sustainable is this recovery—and which industry trends could shape its next phase?

What’s driving the improved outlook?

From renewed biopharma investment and onshoring opportunities to growing demand in oncology and obesity treatments, several forces are reshaping the industry. AI-driven drug discovery and lab automation could provide an additional source of long-term growth.

However, NIH funding uncertainty and China-related risks remain important challenges.

Download the full report for CFRA’s outlook, analysis of nine companies, STARS ratings, 12-month price targets, and assessment of the opportunities and risks ahead.

Download the Report